The company
The company MimeTech Srl was incorporated in December of 2004 by two scientists, Antonio Guarna, Professor of Organic Chemistry, and Federico Cozzolino, Professor of Clinical Laboratory Sciences, both at the University of Firenze, to further...
The technology
At the hub of our technology platform is a cutting-edge series of synthetic neurotrophin mimetics. The flaghship compound, whose name is Udonitrectag, is endowed with potent NGF (Nerve Growth Factor) as well as BDNF (Brain-Derived...
Therapeutic solutions
As the therapeutic approach toward degenerative diseases has so far been inadequate, an enormous medical need still remains unmet. Our technology has proven highly effective in the most reputed animal models of critical human diseases...
Therapeutic solutions
Ophthalmic diseases
Our synthetic neurotrophin mimetics are intended for treatment of corneal...
Read More "Ophthalmic diseases"
Cardiovascular diseases
Acute myocardial infarction (AMI), commonly known as a heart attack, occurs when...
Read More "Cardiovascular diseases"
Neurodegenerative diseases
Our synthetic neurotrophin mimetics may be used for treatment of...
Read More "Neurodegenerative diseases"
Dermatologic diseases
Pressure ulcers, also known as pressure sores, bedsores, and decubitus ulcers, are localized injuries...
Read More "Dermatologic diseases"
Solid organ transplant
Solid organs destined to transplantation undergo ischemic damage as soon...
Read More "Solid organ transplant"
Rare diseases
Rare diseases under evaluation Amyotrophic lateral sclerosis Synonym(s) Charcot disease, Lou...
Read More "Rare diseases"
News
“Udonitrectag” receives orphan drug designation from the European Commission as treatment in solid organ transplantation
On 15/11/2021, orphan designation (EU/3/21/2521) was granted by the European Commission to...
Read More "“Udonitrectag” receives orphan drug designation from the European Commission as treatment in solid organ transplantation"
Recordati receives Orphan Drug Designation for its investigational treatment for neurotrophic keratitis
Recordati today announced that the FDA has granted Orphan Drug Designation to...
Read More "Recordati receives Orphan Drug Designation for its investigational treatment for neurotrophic keratitis"
Recordati licenses an innovative treatment for neurotrophic keratitis
Recordati announced the signing of an exclusive license agreement with MimeTech for...
Read More "Recordati licenses an innovative treatment for neurotrophic keratitis"